Orforglipron (LY3502970) is a small-molecule, non-peptide oral GLP-1 receptor agonist being developed by Eli Lilly. NOTE: Orforglipron is NOT a peptide — it is a synthetic small molecule included here for comparison with peptide-based GLP-1 agonists. It is in Phase III development (ATTAIN trial program) for type 2 diabetes and obesity. Orforglipron has shown promising Phase II results with weight loss approaching injectable GLP-1 agonists, and if approved, would be the first oral non-peptide GLP-1 agonist on the market. Once-daily dosing without food restrictions makes it potentially more convenient than oral semaglutide.
Category: Metabolic / Oral GLP-1 Agonist (Small Molecule). Evidence rating: B (meaningful human data).
Clinical status: Phase III (ATTAIN trial program for T2D and obesity). Eli Lilly expects regulatory submission based on ATTAIN results.
Orforglipron is a non-peptide small molecule that acts as a full agonist at the GLP-1 receptor. Originally discovered by Chugai Pharmaceutical (as OWL833) and licensed to Eli Lilly, it binds to the GLP-1 receptor at a distinct site from the native peptide ligand. Orforglipron stimulates the same…
Research base: 0 registered clinical trials and 8 indexed publications reference Orforglipron.
Safety considerations: Common: nausea (30-40%), vomiting (14-22%), diarrhea (16-22%), constipation — consistent with GLP-1 class but lower than danuglipron BID; GI adverse events are dose-dependent and generally transient, most common during dose titration; Discontinuation due to GI adverse events: approximately 10-17% across dose groups, lower than danuglipron BID.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-08-12.
Related peptides: Danuglipron.
Compare: Orforglipron vs Danuglipron.
No. Orforglipron is a synthetic small molecule (non-peptide) that activates the GLP-1 receptor. It is fundamentally different from peptide-based GLP-1 agonists. It is included on PeptideAtlas for comparison because it targets the same receptor as peptide GLP-1 drugs.
Oral semaglutide (Rybelsus) is a peptide requiring an absorption enhancer (SNAC), empty stomach, and 30-minute fasting. Orforglipron is a small molecule that can be taken without food restrictions. Phase II weight loss with orforglipron (up to -14.7%) may exceed oral semaglutide 14 mg, though head-to-head comparison has not been conducted.
Eli Lilly has Phase III ATTAIN trials underway. If results are positive, regulatory submission is expected. However, Phase III timelines are not fixed, and FDA review adds additional time. The earliest possible approval would likely be 2025-2026.
Most GLP-1 agonists require subcutaneous injection, which some patients find burdensome. An oral pill without food restrictions could dramatically expand the number of patients willing to start GLP-1 therapy. If orforglipron matches injectable efficacy, it could reshape the obesity/diabetes treatment landscape.
Both are oral non-peptide GLP-1 agonists. Orforglipron has a longer half-life (25-36 hours), enabling once-daily dosing, and showed lower GI discontinuation rates in Phase II. Danuglipron had to pivot from twice-daily to modified-release once-daily dosing due to tolerability issues. Orforglipron is generally considered the more advanced and more promising candidate.